Novo Nordisk A/S (NVO)vsSandisk Corp (SNDK)
NVO
Novo Nordisk A/S
$42.96
-1.81%
HEALTHCARE · Cap: $194.70B
SNDK
Sandisk Corp
$1,559.32
+11.54%
TECHNOLOGY · Cap: $278.63B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 2386% more annual revenue ($327.80B vs $13.18B). NVO leads profitability with a 37.2% profit margin vs 34.2%. NVO trades at a lower P/E of 10.3x. NVO earns a higher WallStSmart Score of 73/100 (B).
NVO
Strong Buy73
out of 100
Grade: B
SNDK
Strong Buy70
out of 100
Grade: B
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 60 in profit
Keeps 37 of every $100 in revenue as profit
Strong operational efficiency at 61.6%
Earnings expanding 67.1% YoY
Generating 12.0B in free cash flow
Mega-cap, among the largest globally
Every $100 of equity generates 33 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 70.0%
Revenue surging 251.0% year-over-year
Earnings expanding 618.0% YoY
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Trading at 16.8x book value
Grey zone — moderate risk
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : NVO
The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 37.2% and operating margin at 61.6%. Revenue growth of 24.0% demonstrates continued momentum.
Bull Case : SNDK
The strongest argument for SNDK centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 34.2% and operating margin at 70.0%. Revenue growth of 251.0% demonstrates continued momentum.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio.
Bear Case : SNDK
The primary concerns for SNDK are Price/Book, Altman Z-Score, P/E Ratio. A P/E of 64.1x leaves little room for execution misses.
Key Dynamics to Monitor
SNDK is growing revenue faster at 251.0% — sustainability is the question.
NVO generates stronger free cash flow (12.0B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVO scores higher overall (73/100 vs 70/100), backed by strong 37.2% margins and 24.0% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Sandisk Corp
TECHNOLOGY · COMPUTER HARDWARE · USA
Sandisk Corporation (Ticker: SNDK) is a U.S.-based technology company that develops, manufactures, and sells data storage products and solutions built on NAND flash memory technology, including solid-state drives (SSDs), embedded storage, memory cards, and USB flash drives for consumer, enterprise, and cloud computing markets.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?